Author: Liu, Hejun; Yuan, Meng; Huang, Deli; Bangaru, Sandhya; Zhao, Fangzhu; Lee, Chang-Chun D.; Peng, Linghang; Barman, Shawn; Zhu, Xueyong; Nemazee, David; Burton, Dennis R.; van Gils, Marit J.; Sanders, Rogier W.; Kornau, Hans-Christian; Reincke, S. Momsen; Prüss, Harald; Kreye, Jakob; Wu, Nicholas C.; Ward, Andrew B.; Wilson, Ian A.
Title: A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection Cord-id: bm0b98pa Document date: 2021_4_15
ID: bm0b98pa
Snippet: Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutr
Document: Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody CV38-142 in complex with the receptor binding domains from SARS-CoV-2 and SARS-CoV. Recognition of the N343 glycosylation site and water-mediated interactions facilitate cross-reactivity of CV38-142 to SARS-related viruses, allowing the antibody to accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, notably COVA1-16, to enhance neutralization of SARS-CoV and SARS-CoV-2, including circulating variants of concern B.1.1.7 and B.1.351. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and protect against zoonotic SARS-related coronaviruses.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adjacent spike: 1
- acute sars cov respiratory syndrome coronavirus and long term efficacy: 1, 2, 3, 4
- acute sars cov respiratory syndrome coronavirus and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date